title: Statin use and neurologic morbidity after coronary artery bypass grafting: A cohort study.
abstract: BACKGROUND
  Statin use before surgery has been associated with reduced morbidity and mortality after vascular surgery. The effect of preoperative statin use on stroke and encephalopathy after coronary artery bypass grafting (CABG) is unclear.
  
  
  METHODS
  A post hoc analysis was undertaken of a prospectively collected cohort of isolated CABG patients over a 10-year period at a single institution. Primary outcomes were stroke and encephalopathy. Univariable analyses identified risk factors for statin use, which were applied to a propensity score model using logistic regression and patients were divided into quintiles of propensity for statin use. Controlling for propensity score quintile, the odds ratio (OR) of combined stroke and encephalopathy (primary endpoint), cardiovascular mortality, myocardial infarction, and length of stay were compared between statin users and nonusers.
  
  
  RESULTS
  There were 5,121 CABG patients, of whom 2,788 (54%) were taking statin medications preoperatively. Stroke occurred in 166 (3.2%) and encephalopathy in 438 (8.6%), contributing to 604 patients (11.8%) who met the primary endpoint. The unadjusted OR of stroke/encephalopathy in statin users was 1.053 (95% confidence interval [CI] 0.888-1.248, p = 0.582). Adjustment based on propensity score resulted in balance of stroke risk factors among quintiles. The propensity score-adjusted OR of stroke/encephalopathy in statin users was 0.958 (95% CI 0.784-1.170, p = 0.674). There were no significant differences in cardiovascular mortality, myocardial infarction, or length of stay between statin users and otherwise similar nonusers.
  
  
  CONCLUSIONS
  In this large data cohort study, preoperative statin use was not associated with a decreased incidence of stroke and encephalopathy after coronary artery bypass grafting.
authors.affiliation: Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. mkoenin1@jhmi.edu
authors.forename: M A
authors.initials: MA
authors.lastname: Koenig
authors.forename: M A
authors.initials: MA
authors.lastname: Grega
authors.forename: M M
authors.initials: MM
authors.lastname: Bailey
authors.forename: L D
authors.initials: LD
authors.lastname: Pham
authors.forename: S L
authors.initials: SL
authors.lastname: Zeger
authors.forename: W A
authors.initials: WA
authors.lastname: Baumgartner
authors.forename: G M
authors.initials: GM
authors.lastname: McKhann
mesh_terms: D000368:Aged; D001927:Brain Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015331:Cohort Studies; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D016208:Databases, Factual; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D057216:Propensity Score; D011446:Prospective Studies; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D017211:Treatment Failure
chemical_list: D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors